Downloads: 12 | Views: 439 | Weekly Hits: ⮙2 | Monthly Hits: ⮙2
Research Paper | Pharmaceutical Science | India | Volume 11 Issue 9, September 2022 | Popularity: 5.4 / 10
Formulation and Evaluation of Glibenclamide Immediate Release Tablets
Permula Praveen Kumar, M. Shiroja, Chandrasekhara Rao Baru
Abstract: Glibenclamide Immediate delivery tablets were formed by utilizing a direct pressure strategy involving lactose as a diluent, PVP K 30 as fastener, croscarmellose sodium and crospovidone as deteriorating specialist and magnesium stearate and Aerosil as grease and glidant. Similarity reads were done for the actual combination and the medication was viewed as viable with all excipients utilized in various details. The mix was packed into tablets and was broken down for the boundaries like normal weight, deterioration, friability, thickness, and hardness. Detailing F12 containing crospovidone (7.5mg) shows a fast pace of crumbling when contrasted and different plans. The in-vitro disintegration profiles of F1 and F12 were viewed as per I.P (i.e.) 80% of medication has been delivered inside 30 min. However, the crumbling season of F12 was moderately low (9 sec) when contrasted with the F1 (29 sec) and inferred that F12 is a better plan with 7.5% of crospovidone as it showed in-vitro drug arrival of 100 per cent inside 30 min. Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. It is recommended that it be taken together with diet and exercise. It may be used with other antidiabetic medication. It is not recommended for use by itself in type 1 diabetes.
Keywords: Antidiabetic Medication, Disintegration profiles, croscarmellose sodium and crospovidone as deteriorating specialist
Edition: Volume 11 Issue 9, September 2022
Pages: 624 - 627
DOI: https://www.doi.org/10.21275/SR22912134858
Please Disable the Pop-Up Blocker of Web Browser
Verification Code will appear in 2 Seconds ... Wait